Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. TOP PLAYER POSITIONING, 2015
3.5. PATIENTS/PREVALENCE OVERVIEW
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. High risk of hypogonadism in geriatric population
3.6.1.2. Lifestyle issues
3.6.1.3. Rise in infertility rates
3.6.1.4. Increased awareness level lead to market growth

3.6.2. Restraints

3.6.2.1. Cautions & warnings issued by FDA against the side effects of TRT
3.6.2.2. Social taboos

3.6.3. Opportunity

3.6.3.1. Technological advancements

Chapter: 4 MALE HYPOGONADISM MARKET, BY THERAPY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. TESTOSTERONE REPLACEMENT THERAPY

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size & forecast

4.3. GONADOTROPIN AND GONADOTROPIN RELEASING HORMONES THERAPY

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size & forecast
4.3.4. LH

4.3.4.1. LH market size and forecast

4.3.5. FSH

4.3.5.1. FSH market size and forecast

4.3.6. hCG

4.3.6.1. hCG market size and forecast

4.3.7. Gonadotropin-releasing hormone

4.3.7.1. GnRH market size and forecast

Chapter: 5 MALE HYPOGONADISM MARKET, BY DRUG DELIVERY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. TOPICAL GELS

5.2.1. Market size and forecast

5.3. INJECTABLES

5.3.1. Market size and forecast

5.4. TRANSDERMAL PATCHES

5.4.1. Market size and forecast

5.5. OTHERS

5.5.1. Market size and forecast

Chapter: 6 MALE HYPOGONADISM MARKET, BY TYPE

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. KLINEFELTERS SYNDROME

6.2.1. Market size and forecast

6.3. PITUITARY DISORDERS

6.3.1. Market size and forecast

6.4. KALLMANN SYNDROME

6.4.1. Market size and forecast

6.5. OTHER

6.5.1. Market size and forecast

Chapter: 7 MALE HYPOGONADISM MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. China market size and forecast
7.4.5. Japan market size and forecast
7.4.6. India market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and Opportunities
7.5.3. Market size and forecast
7.5.4. Latin America market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. ABBVIE INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance

8.2. ALLERGAN, PLC

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. ASTRAZENECA PLC.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance

8.4. BAYER AG

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Business performance

8.5. ELI LILLY AND COMPANY LIMITED

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments

8.6. ENDO INTERNATIONAL PLC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments

8.7. FERRING HOLDING S.A.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments

8.8. FINOX BIOTECH (FINOX AG)

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments

8.9. IBSA INSTITUT BIOCHIMIQUE SA

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance

8.10. LABORATOIRES GENEVRIER S.A.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments

8.11. MERCK & CO., INC.

8.11.1. Company overview
8.11.2. Company snapshot
8.11.3. Operating business segments
8.11.4. Business performance

8.12. TEVA PHARMACEUTICAL INDUSTRIES LIMITED

8.12.1. Company overview
8.12.2. Company snapshot
8.12.3. Operating business segments
8.12.4. Business performance
8.12.5. Key strategic moves and developments